Overview
CollPlant Q3 2025 revenue increased significantly due to higher rhCollagen product sales
Company announces 25% workforce reduction to extend cash runway
CollPlant expands North American distribution through new U.S. logistics partnership
Outlook
CollPlant expects North American logistics center to be operational this quarter
Company plans to prioritize collaboration with AbbVie in 2026
CollPlant seeks strategic partner for regenerative breast implant development
Result Drivers
RH COLLAGEN SALES - Increased sales of rhCollagen products contributed to revenue growth
ABBVIE MILESTONE PAYMENT - $2 mln milestone payment from AbbVie boosted revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
9M Revenue | $2.30 mln | ||
9M Adjusted EPS | -$0.58 | ||
9M EPS | -$0.69 | ||
9M Adjusted Net Income | -$7 mln | ||
9M Net Income | -$8.30 mln | ||
9M Operating Expenses | $10 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Collplant Biotechnologies Ltd is $11.50, about 80.5% above its November 25 closing price of $2.24
Press Release: ID:nPn9sb26Va
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)